Vishal Verma

20200218676, Jul 9, 2020

Mar 20, 2020

16/825538

- Santa Clara CA, US
James R. HARRIS - Chandler AZ, US
Ziye YANG - Shanghai, CN
Vishal VERMA - Chandler AZ, US
Changpeng LIU - Shanghai, CN
Chong HAN - Shanghai, CN
Benjamin WALKER - Chandler AZ, US

G06F 13/16
G06F 9/50

Examples herein relate to polling for input/output transactions of a network interface or a storage device, or any peripheral device. Some examples monitor clock cycles spent checking for a presence of input/output (I/O) events and processing I/O events and monitor clock cycles spent checking for presence of I/O events without completing an I/O event. Central processing unit (CPU) core utilization can be based on clock cycles spent checking for a presence of I/O events and processing I/O events and clock cycles spent checking for presence of I/O events without completion of an I/O event. For example, if core utilization is below a threshold, frequency of the core can be reduced for performing polling of I/O events. If core utilization is at or above the threshold, frequency of the core can be increased used to performing polling of I/O events.

20140242027, Aug 28, 2014

Feb 18, 2011

13/579399

Ashok Arasappan - Rahway NJ, US
F. George Njoroge - Carmel IN, US
Cecil D. Kwong - Homewood AL, US
Subramaniam Ananthan - Birmingham AL, US
Frank Bennett - Cranford NJ, US
Francisco Velazquez - Clinton NJ, US
Vinay Girijavallabhan - Denville NJ, US
Yuhua Huang - Westfield NJ, US
Hollis S. Kezer - Hoover AL, US
Joseph Maddry - Birmington AL, US
Robert C. REynold - Birmington AL, US
Abhijit Roychowdhury - Homewood AL, US
Anita T. Fowler - Irondale AL, US
Ling Tong - Warren NJ, US
Seong Heon Kim - Livington NJ, US
Malcolm MacCoss - Seabrook island SC, US
Srikanth Venkatraman - Edison NJ, US
vishal Verma - Jersey City NJ, US

Southern Research Institute - Birmingham AL
Merck Sharp & Dohne Corp. - Rahway NJ

C07D 513/04
C07D 417/04
A61K 45/06
C07D 417/14
C07D 491/048
A61K 31/506

424 854, 544324, 514275, 514 44 A, 4241841, 4241591, 544230, 51421021

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R, X, Y, Z, R, R, R, R, R, R, R, R, R, Rand n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

20140235567, Aug 21, 2014

Jul 10, 2012

14/232540

Vishal A. Verma - Jersey City NJ, US
Ashok Arasappan - Bridgewater NJ, US
F. George Njoroge - Carmel IN, US
Vinay Girijavallabhan - Denville NJ, US
Stephane L. Bogen - Somerset NJ, US
Qun Dang - Westfield NJ, US
David B. Olsen - Lansdale PA, US

C07H 19/14
A61K 45/06
A61K 31/7056
A61K 31/7064

514 49, 536 272, 536 267

The present invention relates to 5′-Substituted Nucleoside Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein B, X, Y, Z, R, R, Rand R are as defined herein. The present invention also relates to compositions comprising at least one 5′-Substituted Nucleoside Derivative, and methods of using the 5′-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

20140221304, Aug 7, 2014

Jul 10, 2012

14/232536

Vishal A. Verma - Jersey City NJ, US
Ashok Arasappan - Bridgewater NJ, US
F. George Njoroge - Carmel IN, US
Kevin X. Chen - Edison NJ, US

C07H 19/06
C07H 19/16
C07H 19/20
A61K 31/7056
A61K 31/7072
A61K 31/708
A61K 31/7076
A61K 45/06
C07H 19/10
A61K 31/7068

514 48, 536 285, 536 268, 536 2853, 536 2851, 536 2781, 536 267, 514 49, 514 50, 514 51, 514 45

The present invention relates to 5′-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R, R, Rand R are as defined herein. The present invention also relates to compositions comprising at least one 5′-Substituted Nucleoside Analog, and methods of using the 5′-Substituted Nucleoside Analogs for treating or preventing HCV infection in a patient.

20140154211, Jun 5, 2014

Apr 11, 2012

14/111687

Vinay Girijavallabhan - Kenilworth NJ, US
F. George Njoroge - Carmel IN, US
Stephane Bogen - Somerset NJ, US
Vishal Verma - San Francisco CA, US
Frank Bennett - Cranford NJ, US
Angela Kereles - Plainfield NJ, US
Ashok Arasappan - Bridgewater NJ, US
Dmitri Pissarnitski - Scotch Plains NJ, US
Qun Dang - Westfield NJ, US
Ian Davies - Princeton NJ, US
David B. Olsen - Lansdale PA, US
Andrew Stamford - Chatham NJ, US
Joseph P. Vacca - Telford PA, US

A61K 31/7072
A61K 31/7068
A61K 45/06
C07H 17/02

424 857, 536 285, 514 49, 536 2781, 514 45, 536 2853, 514 50, 536 268, 536 267, 514 48, 536 2614, 536 2612, 536 2626

The present invention relates to 2′-Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, X, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one 2′-Substituted Nucleoside Derivative, and methods of using the 2′-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.